Longer mirdametinib treatment increased confirmed and deep responses as treatment-related adverse effects declined in neurofibromatosis type 1 tumors.
|Articles|March 4, 2011
Oncology Nursing News
- December 2010
- Volume 4
- Issue 6
Bone Loss Drugs Increase Stroke Risk in Patients With Cancer
Author(s)Onclive Team
Older patients with cancer taking bisphosphonates for bone metastases are at modestly increased risk
Advertisement
Older patients with cancer taking bisphosphonates for bone metastases are at modestly increased risk for atrial fibrillation and stroke. According to a study published online in the Journal of Clinical Oncology, the absolute risk for these patients within 6 years of starting bisphosphonate treatment was approximately 8% for all supraventricular tachycardia events and 4% for stroke.
Articles in this issue
over 15 years ago
Net Guides: Melanomaover 15 years ago
Net Guides: Bone Metastasesover 15 years ago
Yoga for Cancer Careover 15 years ago
FDA Updates: March 7, 2011over 15 years ago
The Future of Nursingover 15 years ago
Net Guides: Liver Cancerover 15 years ago
Net Guides: Carcinoma of Unknown Primary Orginover 15 years ago
Integrative Medicine and Cancer Treatmentover 15 years ago
Reimbursement for Nurse Navigation: It Can Be Doneover 15 years ago
Tools to Help Patients Navigate Their Treatment PathAdvertisement
Related to this article
Age, geographic location, transportation barriers, and language and communication barriers may limit patient opportunities to participate in research.
Retrospective data tie longer survival with niraparib maintenance to homologous recombination deficiency after complete primary debulking.
Exploratory BEHOLD-1 data show responses to mocertatug rezetecan in platinum-resistant ovarian cancer across B7-H4 expression levels.
Updated BEHOLD-1 data show mocertatug rezetecan at its selected dose produced lasting responses in platinum-resistant ovarian cancer.
Are we ready to “take that fork in the road” and move palliative/supportive care into routine cancer care?
Misty D. Shields, MD, PhD, answers questions on ADCs, tarlatamab sequencing, first-line maintenance, subtyping, and transformed SCLC.
Keith Flaherty, MD, FAACR, discusses the 2026 AACR Cancer Progress Report and how the oncology field can build on the report’s findings.
Advertisement
Advertisement
Trending on OncLive
1
Dr Gleave on Selecting Patients for Perioperative Therapy in High-Risk Prostate Cancer
2
Vorasidenib Elicits Early Metabolic Responses in IDH-Mutant Glioma
3
Mirdametinib Deepens Responses in NF1-Associated Plexiform Neurofibroma
4
Cross Currents: New Frontiers in ADC Therapy for Breast Cancer
5